Canadian company says Manitoba isn't giving up on its vaccine, despite threat to leave country

Manitoba's interest in a COVID-19 vaccine developed by a Calgary-based company hasn't waned, despite the developerthreateningto move their operations overseas.

Brad Sorenson, the CEO of Providence Therapeutics, said on Wednesdayhis office is in "constant communication" at least twice a week with officials from Manitoba, the only Canadian jurisdiction committingto purchase their vaccine so far.

"If we had the same level of support federally that we're receiving in Manitoba, this would be a much different conversation," Sorenson said.

He was speaking Wednesday, after Providence reported in a news release theirPhase 1 human trial showed their vaccine was at least as effective as other mRNA vaccines, with no serious side effects.

The status of Providence's deal with Manitoba has been questionedafterSorensonsaidlast month his firm wouldpull out of Canada and take its product elsewhere.

When asked if Manitoba's preliminary agreement with Providence was affected, Premier Brian Pallister said last week that no formal contract was signed, but"we'vegot other irons in the fire" to procure domesticvaccines.

Roadblocks for Canadian vaccine developer

The premier has been an staunchdefender of Providence since February, when critics and opposition parties accused Pallister of banking on an untested, underfundedfirm. It is expected Providence's vaccine will not be eligible for federal approval until2022.

Last month, Sorensonsaid he was fed up with federal and provincial governments since his calls for moresubstantial federal support went unanswered.

"I'm moving on, that's where I'm at now. I've prostrated myself at the altar of government in Canada for a year and I've received nothing for it. I'm tired of begging and pleading," he told CBC News last month.

In an interview Wednesday, Sorensonsaid a relocation of Providence'soperations isn't certain, "but we are definitely looking at options."

Regardless of where the company is headquartered, the vaccine would still be manufactured in Canada, he said. Emergent Biosolutions has a Winnipeg facility slated to manufacture the vaccine.

The Manitoba government agreed in February to pay Providence $36 million for its vaccine. The parties settled on a non-refundable up-front payment of $7.2 million, but Sorenson said no money will be exchanged until a formal contract is signed.

He wants to wait until Providencehas more certainty surrounding itsoperations.

"Under no circumstance am I going to enter into an agreement with Manitoba, the only government in Canada that's really stepped up and supported us, andput them at a disadvantage. That's not going to happen," Sorenson said.

He's continually sought financial help from the federal government including a $150 million askthrough an open letter. So far,Ottawa has obtained all of Canada'sCOVID-19 vaccine supply internationally.

More recently, Sorensonhas asked Ottawafor 500 doses of the Pfizer-BioNTech vaccine to be used in a comparator trial for Phase 2 of the clinicaltrial of Providence's vaccines. He said he's received no response after two months of inquiries.

Providence will have to go to a different country for its trial if they don't get a response by Friday, he said.

"We're not going to sit back and wait and have that control our fate. We've got a backup plan."

A spokesperson for Franois-Philippe Champagne, Minister of Innovation, Science and Industry,saidthe federal government has actually provided Providence with "significant federal support."

The firmreceived up to $10 million earlier this year, the spokesperson said.Providence and other vaccine candidates andtherapeutic candidates are also getting a share of $37 million toward development, and an additional $113 million will be available to the most promising of these candidates, they added.

Sorenson acknowledged Canada may have ordered enough vaccines for 2022 already,but"itwould be unethical for me not to make vaccines that could save lives around the world if I have the ability to do so."

Sorensonexpects Canadians to require COVID-19 booster shots for at least a few years.

A positive step for Providence is the results of the Phase 1 trail, which showed the vaccine has "strong virus neutralization capability" compared toother mRNA vaccines, Sorenson said.

He is planning for the Phase 2 trial to start in June in Canada, or elsewhere and a Phase 3 trial after that.

"I'm optimistic,I'm really excited to go head-to-head against Pfizer."